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Abstract 
 
Strangles is a severe equine respiratory infection, caused by the bacterium Streptococcus equi 
subspecies equi affecting horses of all ages and types worldwide. Infected horses suffer from 
fever, coughing and copious nasal discharge as well as abscesses in lymph nodes in the head 
and throat. S. equi invades the body through the mouth or nose of the horse, and previous 
studies have shown that the interaction is dependent on various extracellular proteins, several 
of which have been characterized. In this project one of these proteins, FNE, has been studied. 
FNE is a secreted fibronectin- and collagen- binding protein unique to S. equi. The main 
purpose of this project was to identify the collagen- and fibronectin-binding parts of the 
protein. This was performed by designing primers and truncating the protein from both N- and 
C-termini (Appendix I). The binding capacities of the truncated proteins were assayed by dot 
blotting. To further examine the properties of the truncated proteins inhibition assays with 
antibodies against FNE were performed. Results show that fibronectin binding is restricted to 
the C-terminal part of the protein and that the amino acids GLEGGSS (228 – 234) are 
required for the binding. By contrast, collagen binding regions seem to be present at both N- 
and C-termini, i.e. the collagen binding domain is fairly large. Antibodies seem to be directed 
to the central part of the protein, and consistent with the above results, interaction with 
antibodies inhibits fibronectin- and collagen- binding. The results will hopefully contribute to 
a deeper basic knowledge about S. equi and the FNE protein as well as be important in the 
progress towards the development of a safe and effective vaccine against strangles. 
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Introduction 
 
An immense part of the world, soil, water, the digestive tract etc., is inhabited by bacteria and 
the total number on earth is estimated to 5 x 10
30 
(Whitman et al. 1998). A substantial fraction 
of these bacteria are beneficial and essential for the survival of a vast number of organisms. 
The human colon, for example, has a concentration of 3 x 10
11
 cells g
-1
 and the cattle rumen 2 
x 10
10
 cells ml
-1
 (Whitman et al. 1998). However, a portion of the bacteria on earth are 
pathogenic and cause infectious diseases in plants and animals.  
   One common group of pathogenic bacteria is the genus Streptococcus, of which the 
bacterium Streptococcus equi subsp. equi is an important equine pathogen, responsible for the 
severe and common respiratory infection strangles. At present, there is no cure for the disease 
and it is uncertain if the few available vaccines on the market are safe and efficient enough. In 
addition, little is known about the bacterium and in order to develop either a cure or a safe and 
efficient vaccine against strangles both basic and applied research are required.  
 
The Genus Streptococcus 
The genus Streptococcus contains approximately 40 chain-forming species of microorganisms 
associated with a variety of infections in humans and animals (Vincent 2005, Hardie et al. 
1997). The bacteria were initially observed in wounds in 1874 by Billroth who named them 
‘Streptococcus’, a term derived from the Greek meaning ‘chain of grapes’ (Vincent 2005). 
   Bacteria belonging to the genus Streptococcus are gram positive, spherical or ovoid with a 
diameter of 0.5-2.0 µm (Holt et al. 1994). They are facultative anaerobic chemoorganotrophs 
that require rich media and occasionally also 5 % CO2 for growth; they have a growth 
optimum at 37
o
C (Vincent 2005, Holt et al. 1994). Grown on blood agar, Streptococci 
generate three distinct types of hemolytic patterns on; α (greenish discoloration) β (complete 
clearing) and γ (no hemolysis) (Vincent 2005, Holt et al. 1994).  
   Many streptococci cause diseases in humans and animals, though species responsible for 
infection in humans are often separated from species causing infection in animals. Infections 
vary from mild to life threatening. Remarkably a number of the pathogenic species can be 
found as part of the normal microflora, without causing any harm to the carrier (Hardie et al. 
1997). The bacteria mainly inhabit the mouth and upper respiratory tract, adhering to 
eukaryotic cells by adhesions that recognize and bind components of the extracellular matrix 
(ECM) (Fischetti 2000, Holt et al. 1994). Streptococci can be divided into subgroups based on 
for example biochemical, serological, physiological, clinical properties and genetic 
similarities. One of the most commonly used systems is the Lancefield serological 
classification system, which divides the streptococci into five subgroups based on 
biochemical and physiological properties (Lancefield 1933).    
 
Streptococcus equi 
Streptococcus equi are Gram positive and hemolytic bacteria pathogenic for equids that 
belong to the Lancefield group C (Timoney et al. 2004). The species contain three subspieces, 
equi, zooepidemicus and ruminatorium.   
   S. equi subspecies equi is the equine pathogen responsible for the severe and common 
respiratory infection strangles (Wood et al. 1998). Grown on blood agar it forms mucous 
colonies and generates broad hemolytic zones (β-hemolysis) (Taylor et al. 2006). The most 
virulent isolates are highly encapsulated in a hyaluronic acid capsule containing the M-protein 
SeM, which inhibits phagocytosis by neutrophils and macrophages (Taylor et al. 2006, 
Timoney et al. 2004). In non-capsulated S. equi SeM is denatured and the bacteria are thus 
efficiently phagocytosed (Timoney et al. 2004). Moreover, S. equi produces a number of 
5 
 
toxins, streptolysins (responsible for e.g. β-hemolysis), hyaluronidase, leukocytotoxins and 
mitogens that inhibit host cell responses and hence contribute to disease severity (Taylor et al. 
2006, Timoney et al. 2004).  Furthermore, a number of extracellular proteins with diverse 
functions are anchored to the surface of S. equi. The genome of S. equi subsp. equi, published 
at Sanger Institute, is 2,253,793 bp in length, with a G+C content of 41 %. Moreover, the 
genome shows a remarkably close relationship (97 % identity) to S. equi subsp. 
zooepidemicus, suggesting evolution of S. equi from an ancestral S. zooepidemicus (Timoney 
et al. 2004, The Sanger Institute 2006) The two subspecies can however be separated by the 
inability of S. equi subsp. equi to ferment lactose, ribose and sorbitol (Wood et al.1998). 
   S. equi subsp. zooepidemicus is a non host adapted pathogen present in the normal 
microflora of a wide variety of mammals. The bacterium is an opportunistic pathogen causing 
infections in the respiratory tract only in situations when the body’s immune response is 
lowered, such as during stress, heat and viral infections, and can then be fatal (Lannergård 
2006, Timoney et al. 2004).  
   S. equi subsp. ruminatorium is a recently identified bacterium displaying 70 % identity to S. 
equi subsp. zooepidemicus. The bacterium is frequently detected in milk samples from sheep 
and goats affetcted with clinical or subclinical mastitis (Fernández et al. 2004). However, 
studies have established a significant genomic and phenotypic divergence between the 
species, separating ruminatorium from equi and zooepidemicus (Lannergård 2006). 
 
Strangles 
Strangles is a severe equine respiratory infection disease caused by the bacterium 
Streptococcus equi subspecies equi affecting horses of all ages and types worldwide. The 
disease was first reported by Jordanus Ruffus in 1251 and is one of the most commonly 
diagnosed equine diseases (Sweeney et al. 2005, Taylor et al. 2006). Strangles comprise 
almost 30 % of the infectious disease episodes reported to the International Collating Centre 
and has a morbidity of 85-100 % in susceptible populations and a mortality of 4-8 % 
(Harrington et al. 2002, Taylor et al. 2006). Moreover, the extended disease course, that may 
last for months or even years, and prolonged recovery period in concert with associated 
serious complications contribute major economic deficits to the equine industry (Harrington et 
al. 2002, Taylor et al. 2006). 
   The disease is characterized by a rapid increase in body temperature to the range of 39-41°C 
that persists throughout the disease course and is followed by coughing and copious nasal 
discharge (Sweeney et al. 2005, Taylor et al. 2006). A few days after onset the major clinical 
sign, development of abscesses in lymph nodes around the head and throat, is rapidly initiated 
(Sweeney et al. 2005, Taylor et al. 2006). Abscesses around the throat may cause swallowing 
difficulties and in severe cases also breathing difficulties, hence the name ‘strangles’ (Waller 
et al. 2007, Taylor et al. 2006). In up to 10% of cases a fatal condition entitled ‘bastard 
strangles’ occurs, where abscesses form in lymph nodes of other body organs (Waller et al. 
2007, Harrington et al. 2002, Taylor et al. 2006). Disease symptoms and severity of the 
disease are often correlated to the immune status and age of the horse, where older horses 
often show a milder form of the disease and younger horses more frequently develop a severer 
form (Sweeney et al. 2005, Taylor et al. 2006). 
   S. equi invades the body through the mouth or nose of the horse and attaches to the mucous 
membrane and lymphoid tissue in the upper respiratory tract. The bacterium quickly 
penetrates the cells and spreads to the lymph nodes with the blood or via lymphatic channels, 
resulting in abscesses. Bacteria can be detected in nasal discharge 24-48 hours after the first 
temperature peak. Presence of S. equi in nasal sheddings usually persists for two to three 
weeks, but has been detected for longer periods, up to 39 months, even after dissipation of 
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clinical signs (Sweeney et al. 2005, Taylor et al. 2006). The bacterium can, in infected horses, 
also be found in the throat and abscesses (Timoney et al. 2004).  
   The source of infection is thought to be normal nasal secretion, either from horses that have 
developed the disease or from infected horses without clinical signs (Sweeney et al. 2005). S. 
equi is transmitted through direct horse-to-horse contact as well as through humans, clothes, 
shared equipment, feed and contaminated water (Waller et al. 2007, Sweeney et al. 2005, 
Taylor et al. 2006).  
   Strangles is a difficult disease to treat as S. equi is susceptible to several antibiotics in vitro, 
but not in vivo due to the antimicrobials’ inability to break through the abscess capsule 
(Harrington et al. 2002, Taylor et al. 2006). However, immediate treatment with antibiotics in 
the early acute phase may be successful and prevent development of abscesses, even though 
treated horses often remain susceptible to reinfection (Waller et al. 2007, Sweeney et al. 
2005). The majority of animals have after four to six weeks succeeded in eliminating S. equi 
and thus recovered from the disease (Waller et al. 2007). Lasting immunity to the disease is 
developed after recovery in approximately 75 % of the affected individuals (Sweeney et al. 
2005). 
   The clinical diagnosis is confirmed by detection of S. equi in nasal washes or swabs taken 
from abscesses and the upper part of the throat using microbial and PCR screening (Waller A. 
et al. 2007, Taylor et al. 2006). PCR screening is quick and accurate although it must be 
confirmed by culture since the method cannot discriminate between dead and alive organisms 
(Waller et al. 2007, Harrington et al. 2002). IDEXX laboratories in the US have an alternative 
diagnostic method available, based on detection of antibodies directed to the S. equi protein 
SeM (Waller et al. 2007, Taylor et al. 2006). 
 
Extracellular Proteins of S. equi 
An important feature for infection progression and survival of microorganisms inside the host 
is interaction with and adherence to host tissues (Lannergård 2006, Harrington et al. 2002).  
   The cell wall of streptococci and other Gram-positive bacteria lacks an outer membrane and 
is composed of thick cross-linked peptidoglycan. This construction, serving as a physical 
barrier, protects the bacteria against lysis and works as a base for attachment of surface 
exposed molecules such as proteins, teichoic acids and polysaccharides (Lannergård 2006, 
Fischetti 2000). The surface exposed molecules (Fig. 1) have a vast diversity of functions, e.g. 
binding to host tissues, plasma proteins and specific immune system components, and are 
believed to be important for survival of the organism in a hostile environment, for example 
the host (Lannergård 2006, Harrington et al. 2002, Fischetti 2000).  
   Cell wall-anchored proteins among streptococci are most commonly attached to the cell by 
three different mechanisms; sortase-mediated attachment of proteins with LPxTG-type motifs, 
N-terminal linkage to lipoproteins and by charge or hydrophobic interaction. In S. equi the 
majority of the cell wall anchored proteins are believed to be sortase- attached (Lannergård 
2006, Fischetti 2000). These proteins are characterized by a C-terminal sorting signal and a 
sequence starting with an LPxTG motif, subsequently located at the outer surface of the cell 
membrane (Lannergård 2006).  
   Proteins involved in the adherence of the bacterium to different substrata in the host are 
called adhesions and are believed to increase the chances for survival of the bacterium until it 
reaches tissues and surfaces where colonization and growth are favorable. The microbial 
surface components recognizing adhesive matrix molecules (MSCRAMMs) are the most well 
studied group of streptococcal adhesins. Fibronectin and fibrinogen are two extracellular 
matrix components serving as host ligands for streptococcal adhesins and genes for at least 
two Fn-binding proteins have been demonstrated in S. equi (Harrington et al. 2002).  
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  Furthermore S. equi produces a number of secreted proteins that are labeled with an N-
terminal signal peptide which is removed during translocation over the membrane. This group 
of proteins includes a number of enzymes and toxins as well as at least one fibronectin- and 
collagen-binding protein, FNE (Lannergård 2006).  
 
 
 
Figure 1. Schematic representation of the gram positive bacterial cell wall with lipoprotein connected 
to the membrane, sortase-anchored protein, protein linked by charge or hydrophobic interaction and a 
secreted protein. Picture modified by Lannergård (2006).  
 
FNE 
Fibronectin (Fn) binding characteristics have been reported for several pathogenic bacteria, 
such as coagulase- positive staphylococci and streptococci of serological groups A, B, C, and 
G. Studies of the Fn-binding proteins have revealed that all contains a C-terminal repetitive 
domain which binds Fn and that Fn-binding proteins have been shown to mediate the invasion 
of host cells without the need for other bacterial factors (Lindmark et al. 1996b, Lannergård et 
al. 2005). 
   FNE, also referred to as Eq52, is a secreted Fn- and collagen-binding protein found in S. 
equi. The protein is composed of 303 amino acids and encoded by the gene fne. FNE shows 
100 % homology to the first 300 amino acids of the N-terminal of the Fn- and collagen 
binding protein FNZ from S. zooepidemicus (Fig. 2 and Appendix I). FNZ is a cell wall 
anchored Fn- and collagen- binding protein composed of 597 amino acids encoded by the 
gene fnz (Lindmark et al. 1996b, Lidén et al. 2006). FNZ contains two Fn-binding sites, one 
in the N-terminal that binds to the 40 kDa collagen-binding domain of Fn and one in the C-
terminal binding to the 29 kDa heparin/fibrin- binding fragment of Fn and is thought to 
contribute to bacterial adhesion (Harrington et al. 2002, Lidén et al. 2006, Lannergård et al. 
2005). A deletion of a base in the fne sequence has introduced a stop codon in the S. equi FNE 
open reading frame, thus creating a truncated protein lacking the C-terminal half of the FNZ 
protein (Lindmark et al. 2001). FNE (Fig. 2) binds to Fn within the 40-kDa fragment 
(Lannergård et al. 2005). The C-terminal of FNZ contains the cell wall anchoring motif and 
the absence of the C-terminal part in the FNE protein explains why FNE is secreted 
(Lindmark et al. 2001). Moreover, Fn-binding assays have shown that S. equi binds three to 
tenfold less fibronectin than S. zooepidemicus, which could be explained by the absence of the 
C-terminal of FNZ (Lindmark et al. 2001).  
   The S. equi genome contains genes for five proteins similar to FNE; FNEB, FNEC, FNED, 
FNEE and FNEF, where the similarities to FNE are located in the N-terminal ends. FNEC, 
FNEE and FNEF are predicted to be cell wall anchored whereas FNED contains a stop codon 
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in the middle of the gene which has created a truncated protein without a C-terminal cell wall 
sorting signal and is thus predicted to be secreted. FNEB is shown to bind fibronectin and 
FNEC, FNED and FNEF are shown to bind collagen. In addition to FNE, FNEE is the only 
protein that binds both fibronectin and collagen (Lannergård J. 2006). In addition S. equi also 
encodes a second extracellular fibronectin-binding protein named SFS (Lindmark and Guss, 
1999). 
   Since FNE is a secreted protein is not likely to contribute to bacterial adherence in the order 
of the FNZ protein. Though, previous studies (Lidén et al. 2006, Lidén et al. 2008) show that 
the FNE homolog FNZN (N-terminal part of the FNZ protein) induces collagen gel 
contraction, by linking cell-surface bound fibronectin to collagen type I, and thus may 
counteracting edema formation. Edema formation is thought to make bacteria more available 
for the innate immune system by encapsulating the infection and is caused as a consequence 
of the lowered interstitial fluid pressure (IFP), controlled by connective tissue cells (Lidén et 
al. 2008). The studies made by Lidén et al show that FNE stimulates interaction between 
native collagen type I and fibronectin and it is further presumed that FNE simultaneously can 
bind fibronectin and collagen. Moreover it has been shown (Lidén et al. 2006, Lidén et al. 
2008) that fibronectin expression of cells is needed for FNE adherence and that cell surface 
located integrins are receptors for the fibronectin-FNE-collagen fiber complexes as well as 
mediators for the intracellular force required for contraction. The contraction is likely to be 
formed by FNE forming a molecular link between collagen fibers and integrin bound cell 
surface exposed fibronectin (Lidén et al. 2008).  
 
 
 
Figure 2. Schematic presentation of FNE and FNZ, modified from Lannergård (2006), with the signal 
sequence labeled SS and the gray part of FNZ representing the C-terminal Fn-binding regions. 
Percents of similarity are based on identical amino acids in the specific region. 
 
Fibronectin 
Fibronectin (Fn) is a large glycoprotein important for cell adhesion to the extra cellular matrix 
(ECM), guiding of cell migration in the embryo, morphology and thrombosis (Lannergård J. 
2006, Alovskaya A. 2007). Furthermore, the protein is a vital ligand for binding of gram- 
positive cocci to the host tissue (Lindmark H. et al. 1996). Fibronectin (Fig. 3) is composed of 
two almost identical subunits with a size of 250-280 kDa each, linked by disulfide bonds in 
the C-terminal ends of the molecules (Alberts B. et al. 2002, Alovskaya A. 2007). Each 
subunit is folded into domains with diverse functions, which in turn are composed of smaller 
and serially repeated modules, generally encoded by a separate exon (Alberts B. et al. 2002). 
Approximately 90 % of the protein is composed of these repetitive sequences (Alovskaya A. 
2007). The different modules contain binding sites for various molecules, such as heparin, 
fibrin, bacteria, collagen and cells (Lannergård J. 2006, Alovskaya A. 2007). The F3 module 
(Fig. 3) is the most common module among vertebrates and contains binding sites for several 
membrane receptors and ECM components important for the assembly of the ECM (Alberts 
B. et al. 2002, Lannergård J. 2006). Fibronectin is found both in soluble and insoluble forms 
in the body. The soluble forms, thought to enhance blood clotting and wound healing, are 
9 
 
found in plasma and thus circulate in blood and other body fluids. All other forms of 
fibronectin assemble as fibrills on cell surfaces in the ECM (Alberts B. et al. 2002, Alovskaya 
A. 2007). 
 
Fig 3. Schematic presentation of a fibronectin chain (Lannergård 2006). The F3 module is marked 
grey and arrows demonstrate proteolytic digestion sites. Molecular weight and ligand interactions of 
the different fragments are indicated. Chains are linked by disulfide bonds at the C-terminal. 
 
Collagen 
Collagen is a family of proteins that forms a long and rigid right handed helix from three 
polypeptide chains. Collagen comprises approximately 25 % of the protein in the body and is 
further the most abundant structural component of the extracellular matrix (ECM) (Alberts B. 
et al. 2002, Alovskaya A. 2007).  There are 26 different collagen types, all with different 
functions and distribution in tissues (Lannergård J. 2006, Alovskaya A. 2007. However, 
characteristic for all types is the triple helical domain, constructed by a number of Gly-x-y 
repeats, and the abundance of glycines, prolines and hydroxyprolines (Alberts B. et al. 2002, 
Lannergård J. 2006). The molecule is enhanced by covalent bonds between lysine residues 
and hydrogen bonds between hydroxylated and glycosylated prolines and lysines (Alberts B. 
et al. 2002). Collagen can be composed either of three identical chains (homotrimers) or three 
diverse chains (heterotrimers). Based on the polymers formed collagen can be divided into 
two groups, fibril-forming collagens (I, II, III, V och XI), which represent a rather 
homogenous group and the nonfibrillar collagens which represents a heterogenous group. 
Collagen has several diverse functions of which the most important is the formation of highly 
organized polymers, essential for the structure of the ECM (Alovskaya A. 2007). Moreover, 
as collagen fibrils do not elongate at tension they help tendons, bone, cartilage and skin to 
withstand tear, tensile stress and pressure (Alberts B. et al. 2002, Sjaastad O. et al. 2003).  
 
Vaccine 
As antibiotic treatment of strangles is inefficient an effective vaccination against the disease 
would provide excellent disease prevention (Lannergård 2006, Waller et al. 2007).  However, 
progress in development of an effective vaccine is very slow and has been in progress for over 
a century (Lannergård 2006, Timoney et al. 2004). Vaccines based on whole, inactivated cells 
were introduced for the first time in 1940 in Australia. These vaccines were made from heat 
inactivated logarithmic phase cultures with preserved antigens. However, these vaccines 
showed low efficiency and resulted in frequent adverse reactions and were therefore replaced 
with extract vaccines without irritating cell wall components, such as peptidoglycan 
(Lannergård 2006, Waller et al. 2007). Extract vaccines made from proteins released from the 
cell wall by hot acid treatment or mutanolysin were introduced in the US in 1970 (Timoney et 
al. 2004).  
   Vaccines directed against the strongly immunogenic SeM protein have been in development 
and have shown promising results in mouse (Waller et al. 2007, Harrington et al. 2002). 
10 
 
However, these vaccines have given very low protection levels in horses and an explanation 
to this could be the deficient mucosal response otherwise correlated with resistance to 
reinfection (Waller et al. 2007, Timoney et al. 2004). Another identified surface protein, 
hyaluronate associated protein (HAP), has been investigated for vaccine potential. The protein 
showed promising results in mice, but resulted in no protection when given to horses (Waller 
et al. 2007). 
   A live, nonencapsulated mutant of S. equi (Pinnacle I.N.) has been used as an intranasal 
strangles vaccine in the US since 1998. However, the entry of this living mutant of S. equi 
into tissues gives abscess formation as a consequence and accidental contamination of 
injection sites could result in severe cases of strangles (Lannergård 2006, Timoney et al. 
2004). Furthermore, this strain was obtained by random chemical mutagenesis and is 
therefore prone to back mutations, hence reverting the strain back into full virulence. Due to 
this, the vaccine has not been licensed for sale in Europe even though it offers protection 
against strangles for up to 100 % of horses (Lannergård 2006, Waller et al. 2007). 
   However, another live attenuated vaccine strain TW 928 has been licensed for sale in 
Europe under the name Equilis StrepE (Lannergård 2006, Waller et al. 2007). This strain is 
genetically modified at the aroA gene that is involved in cellular metabolism (Waller A. et al. 
2007, Harrington et al. 2002).  The vaccine is given submucosally into the inside of the lip in 
order to reduce injection site reactions and has been shown to reduce development of lymph 
node abscesses for 50 % of horses. However, the vaccine does only provide a three-month 
period of immunity and is only recommended for horses in need of a short period of immunity 
(Lannergård 2006, Waller et al. 2007).  
      The fact that the majority of animals recovering from strangles remain immune against the 
disease for 5 years or longer is not entirely understood, but a combination of mucosal and 
serum immunoglobulins seem to be one explanation and results from earlier studies propose 
that an immune response generated against multiple epitopes is required in order to attain 
satisfying protection against the disease (Lannergård 2006, Waller et al. 2007). Hence, 
vaccines based on several immunogenic surface proteins from S. equi could become an 
alternative to live attenuated vaccines. Successful trials of vaccines directed against multiple 
epitopes, containing the proteins FNZ, SFS and EAG from S. equi, have been performed on 
mouse (Flock, et al. 2004). A similar vaccine including the proteins CNE, SclC and EAG has 
also been in development and did also showing promising results in mouse (Waller et al. 
2007). Another possibility is to use Fn-binding proteins as vaccines. This concept has been 
tested regarding bovine mastitis, using recombinant Fn-binding proteins from Staphylococcus 
aureus. Moreover the N-terminal part of FNZ, resembling FNE, has been used as a 
component in a vaccine giving promising results (Flock et al. 2004). 
 
Aim of the Project 
The main purpose of this project was to identify the collagen- and fibronectin-binding parts of 
the FNE protein. This was performed by designing primers and truncating the protein into 
smaller parts from both N- and C-termini (appendix I). The binding capacities of the truncated 
proteins were assayed by dot blotting. To further examine the properties of the truncated 
proteins inhibition assays with antibodies against FNE were performed.  
   This project was made as a part of an extensive study in which research for an effective and 
safe vaccine against strangles is in progress.  
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Materials and Methods 
 
Bacterial Strains, Plasmids and Growth Conditions 
Escherichia coli strain BL21 and E. coli strain TG1 were used for protein expression. Cells 
were cultured in Luria- Bertani broth (LB) supplemented with ampicillin (50 mg ml
-1
), or on 
LAA plates (Luria- Bertani broth with agar [15 g L
-1
] supplemented with ampicillin [50 mg 
ml
-1
]). All strains were incubated at 37 
o
C. The plasmid pGEX-6P-1 (Appendix II), used for 
expression of recombinant proteins, was obtained from GE Healthcare.  
 
Construction of Clones  
To identify and/or separate the binding sites for fibronectin and collagen in the FNE protein 
12 different truncated constructs of FNE were made, 6 constructs truncated from the C-
terminal and 6 truncated from the N-terminal (appendix I). The constructs were amplified 
using PCR with chromosomal DNA from S. equi as template, Ready To Go
TM
 PCR beads 
(Amersham) and the designed primers shown in table 1. To match the cloning site in the 
pGEX-6X-1 cloning vector cleaving sites for the restriction endonucleases BamHI and XhoI 
were included in the primer sequences. The PCR programme used for constructs eq51c1-c3 and 
eq52n1-n3 was as follows: Step 1 30 seconds at 95 
o
C; Step 2 30 seconds at 50 
o
C and Step 3 
30 seconds at 72 
o
C. For constructs eq52n0, eq52n4-n5 and eq52c4-c6 the following PCR 
programme used: Step 1 15 seconds at 96 
o
C; Step 2 15 seconds at 52 
o
C; Step 3 1 minute at 
72 
o
C. The PCR reaction was run for 29 cycles where after PCR products were analyzed on a 
1.2 % agarose gel and thereafter purified using QIAquick PCR Purification Kit
TM
 (Qiagen).  
 
 
Table 1. Primer sequences (5’ to 3’) for constructs eq52n0 to n5 and eq52c1 to c6 with restriction 
endonuclease (BamHI for forward sequences and XhoI for reverse sequences) cleaving sites 
emphasized.  
Construct Forward primer Reverse primer 
 
eq52n0 GCTTGGATCCGGGTGGAATGATGGAACG GCACCTCGAGGACCCTTCAATCCTGGAAAGG 
eq52n1 GAGAGGATCCTCGCCATATTTTTTGTACGTATCG GCACCTCGAGGACCCTTCAATCCTGGAAAGG 
eq52n2 CTTTGGATCCAAATTGTATTGGCCAGATCAATG GCACCTCGAGGACCCTTCAATCCTGGAAAGG 
eq52n3 TTTAGGATCCGGATACCCCACTAACAAGTCAC GCACCTCGAGGACCCTTCAATCCTGGAAAGG 
eq52n4 TGGAGGATCCGGCCTTGAAGGAGGATC GCACCTCGAGGACCCTTCAATCCTGGAAAGG 
eq52n5 AGGAGGATCCGGTTCACAACAAACTAATGAAG GCACCTCGAGGACCCTTCAATCCTGGAAAGG 
eq52c1 AGCTGGATCCGAGCAGCTTTATTATGGGTGG GGCTCTCGAGTTATTTAGGAATTAAGGTAGAGCC 
eq52c2 AGCTGGATCCGAGCAGCTTTATTATGGGTGG GCTTCTCGAGTTAACCACCCGTATCTTTAAG 
eq52c3 AGCTGGATCCGAGCAGCTTTATTATGGGTGG CACTCTCGAGTTATTTGTAATCTGGAGCATATTG 
eq52c4 AGCTGGATCCGAGCAGCTTTATTATGGGTGG GCTCCTCGAGTTACTTAGAATCCTCTCCTTTAC 
eq52c5 AGCTGGATCCGAGCAGCTTTATTATGGGTGG AATCCTCGAGTTAGTCATGCCCGCCACTTTG 
eq52c6 AGCTGGATCCGAGCAGCTTTATTATGGGTGG AGTCCTCGAGTTATGAGAGTCCTCCATGGAAAC 
 
 
The purified PCR products were digested with BamHI and XhoI in the presence of DTT (1 mM) 
where after an additional purification step was performed. Thereafter products were ligated into the 
pGEX-6P-1 vector and subsequently the plasmid was electroporated into E. coli strain TG1. E. 
coli strain TG1 were cultured on LAA plates over night where after four colonies from each 
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construct were chosen for further analysis. Plasmids were thereafter purified using QIAprep 
Spin Miniprep (Qiagen) and verified on a 1.2 % agarose gel before sent for sequencing at the 
Rudbeck Laboratory, Uppsala for confirmation of correct inserts.  
 
Protein Expression and Purification 
Two clones for each construct (eq52c1-2 and eq52n1-n3) were chosen and transformed into 
the E. coli strain BL21, clones eq52c3-6, eq52n0 and eq52n4-5 were expressed only in E. coli 
strain TG1. Bacteria were spread on LAA plates and cultured over night where after one 
colony from each construct was further cultured in LB-Amp. Protein expression was induced 
on 1 liter cultures, with an OD600 of approximately 0.6, by the addition of 0.1 mM isopropyl 
β-D-1-thiogalactopyranoside (IPTG) (Amersham Biosciences) and incubated over night. Over 
night cultures were thereafter centrifuged for 25 min at 4000 rpm and resuspended in PBS + 
0.1 % TWEEN20 where after cells were lysed by the addition of lysozyme to a final 
concentration of 0.02 mg/ml.  
   Purification of proteins was made using the Glutathione S-transferase (GST) Gene Fusion 
System (Appendix II).  Protein lysates were sonicated, to break down chromosomal DNA, 
and thereafter centrifuged. Glutahione Sepharose
TM
 (GST) High Performance Media (GE 
Healthcare) was washed with PBS + 0.1% TWEEN20 where after supernatants, from he 
preceding step, were added and incubated over night. Subsequently proteins were eluted over 
night using the following elution buffer: 50 mM Tris-HCl, 10 mM reduced glutathione, pH 
8.0. Proteins were thereafter analyzed using SDS-PAGE (Phast System, GE) and dialysed 
against 0.5 x PBS using dialyse tubes (Spectra/Por
®
, Spectrum Laboratories, Inc.) with a 
membrane size of Mw 6- 8 kDa. Protein concentrations (Table 2) were calculated using 
extinction coefficients, based on searches at the ExPASy proteomics server 
(http://expasy.org/), and Lambert Beer’s Law (A = εlc). Constructs eq52c3, eq52c4 and 
eq52c5 were concentrated approximately 3 times using Polyethylene glycol (Sigma Aldrich 
Chemie, Steinheim Germany) where after all constructs were diluted to a concentration of 120 
µg ml
-1
.  
 
 
Table 2. Extinction coefficients at 1mg/ml for the different constructs; eq52c1, eq52c2, eq52c3, 
eq52c4, eq52c5, eq52c6, eq52n0, eq52n1, eq52n2, eq52n3, eq52n4 and eq52n5 (ExPASy-ProtParam, 
2007) respectively.  
 eq52c1 eq52c2 eq52c3 eq52c4 eq52c5 eq52c6 
Extinction coefficient (at 1 mg/ml) 
 
 
Extinction coefficient (at 1 mg/ml) 
1.918 
 
eq52n0 
1.690 
2.043 
 
eq52n1 
1.621 
2.102 
 
eq52n2 
1.612 
1.964 
 
eq52n3 
1.383 
1.960 
 
eq52n4 
1.401 
1.760 
 
eq52n5 
1.429 
 
 
All constructs including wild type FNE protein were further assayed and verified by Western 
blotting of SDS-PAGE gels. Constructs eq52c3-c5 were applied non-diluted and the 
remaining constructs diluted with a concentration of 120 µg ml
-1
. Protein samples/patterns 
from gels were transferred to nitrocellulose filters (Hybond
TM
 C-Extra, 0.45 Micron, 
Amersham Biosciences) in 65°C for 30 minutes and blocked in PBS + 0.1 % TWEEN 20 + 
Casein 0.1 mg ml
-1
 for 30 minutes. Filters were subsequently washed with PBS + TWEEN 
20% where after PBS + 0.1% TWEEN20 + GST antibodies (1µl ml
-1
) (Amersham 
Biosciences) was added and filters were incubated for one hour in room temperature. 
Thereafter filters were washed with PBS + 0.1% TWEEN20 before PBS + 0.1% TWEEN20 + 
secondary antibodies from goat labeled with peroxidase (1µl ml
-1
) (Sigma Aldrich Chemie, 
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Steinheim Germany) was added and incubated for one hour in room temperature. Filters were 
subsequently washed with PBS + 0.1% TWEEN20 and in the last step with PBS where after 
development of filters was made with PBS + 25 % 4-chloronaphtol + H2O2 (0.8 µl ml
-1
). 
 
Protein Interaction Assays 
The ability of the different constructs to bind fibronectin and collagen was assayed by dot 
blotting on nitrocellulose membranes (Hybond
TM
 C-Extra, 0.45 Micron, Amersham 
Biosciences).  Collagen, fibronectin and albumine (negative control) with a concentration of 1 
mg/ml respectively were dotted on filters (Hybond C, Amersham Biosciences) and blocked 
with PBS + 0.1% TWEEN20 + Casein (0.5 mg ml
-1
). Protein constructs and the wild type 
protein FNE (positive control) were added to a final concentration of 2µg/ml to one filter per 
construct and incubated in PBS + 0.1% TWEEN20 in a cold room over night. Thereafter 
filters were washed four times with PBS + 0.1% TWEEN20 where after PBS + 0.1% 
TWEEN20 + GST antibodies (1µl ml
-1
) (Amersham Biosciences) were added to each filter 
respectively. Filters were incubated for 1 hour in room temperature before washed with PBS 
+ 0.1% TWEEN20 and PBS + 0.1% TWEEN20 + Secondary antibodies from goat labeled 
with peroxidase (1µl ml
-1
) (Sigma Aldrich, Steinheim Germany) was added. Filters were 
incubated in room temperature for 1 hour where after washed with PBS + 0.1% TWEEN20 
and subsequently with PBS. Development of filters was made with PBS + 25 % 4-
chloronaphtol + H2O2 (0.8 µl ml
-1
).  
 
Antibody Interaction Assays 
The ability for clones eq52c1-c2 and eq52n1-n3 to interact with antibodies directed against 
the N-terminal part of FNZ (+ 40 amino acids) was assayed by western blotting. Protein 
samples were diluted to a concentration of 120 µg ml
-1
 where after run on two SDS-PAGE 
gels.  Protein samples/patterns from gels were thereafter transferred to nitrocellulose filters 
(Hybond
TM 
ECL
TM
, Amersham) (65°C, 30 minutes) and blocked in PBS + TWEEN 20% + 
casein 0.1 mg ml
-1
 over night. The following day PBS + 0.1% TWEEN20 + serum (4 µl ml
-1
) 
with antibodies against the FNE protein was added to one of the filters (filter 1) and  PBS + 
0.1% TWEEN20 + GST antibodies (1µl ml
-1
) (Amersham Biosciences) was added to the 
second filter (filter 2). Filters were subsequently incubated in room temperature for 2 hours 
where after washed with PBS + 0.1% TWEEN20. Thereafter PBS + 0.1% TWEEN20 + 
secondary antibodies from rabbit labeled with peroxidase (1µl ml
-1
) (Sigma Aldrich, 
Steinheim Germany) was added to filter 1 and PBS + 0.1% TWEEN20 + secondary 
antibodies from goat labeled with peroxidase (1µl ml
-1
) (Sigma Aldrich, Steinheim Germany) 
was added to filter 2. Filters were incubated in room temperature for 1 hour where after 
washed with PBS + 0.1% TWEEN20 and subsequently with PBS. Development of filters was 
made with PBS + 25 % 4-chloronaphtol + H2O2 (0.8 µl ml
-1
). 
 
An additional antibody interaction assay was performed by dot blotting, using antibodies 
against the N-terminal part of FNZ (FNZN, Flock, et al. 2004) generated in rabbit as well as 
five pooled sera from healthy horses and five pooled sera from horses recovered from 
strangles respectively. Protein constructs (4 µl 120 µg ml
-1
 of constructs eq52c1-c2 and 
eq52n0-n5, 4 µl of non-diluted eq52c5 and 12 µl non-diluted eq52c3-c4)  FNE protein (4µl 
100 µg ml
-1
) were blocked on three separate filters; 30 minutes in PBS + TWEEN 20% + 
Casein 0.5 mg ml
-1
.  Filters were thereafter washed in PBS + 0.1% TWEEN20 where after 
PBS + 0.1% TWEEN20 + rabbit antibodies (10 µl ml
-1
) (Sigma Aldrich, Steinheim Germany) 
(filter 1), PBS + 0.1% TWEEN20 + sera from healthy horses (10 µl ml
-1
) (filter 2) and PBS + 
0.1% TWEEN20 + sera from horses recovered from strangles (10 µl ml
-1
) (filter 3) were 
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added to one filter respectively. Incubation was made in room temperature for one hour. 
Filters were subsequently washed with PBS + 0.1% TWEEN20 where after PBS + 0.1% 
TWEEN20 + anti rabbit antibodies (1 µl ml
-1
) (Sigma Aldrich, Steinheim Germany) was 
added to filter 1 and PBS + 0.1% TWEEN20 + anti horse antibodies (1 µl ml
-1
) (Sigma 
Aldrich, Steinheim Germany) was added to filter 1 and 2 respectively. Filters were thereafter 
incubated in room temperature for 1 hour where after washed with PBS + 0.1% TWEEN20 
and subsequently with PBS. Development of filters was made with PBS + 25 % 4-
chloronaphtol + H2O2 (0.8 µl ml
-1
). 
 
Inhibition Assays 
In order to evaluate whether the interaction of antibodies with the constructs could inhibit the 
fibronectin and collagen binding properties an inhibition assay was performed.  
   Constructs eq51c6, eq52n0 and eq52n4 (24 mg ml
-1
) were mixed with antibodies against the 
N-terminal part of FNZ (FNZN) (800 µl ml
-1
) and incubated in room temperature for one 
hour. Collagen, fibronectin and albumin (negative control) with a concentration of 1 mg/ml 
respectively were dotted on filters (Hybond C, Amersham Biosciences) and blocked with PBS 
+ 0.1% TWEEN20 + Casein (0.5 mg ml
-1
) for 30 minutes before the protein-antibody 
mixtures were added to the filters respectively. Filters were incubated for one hour in room 
temperature where after washed with PBS + 0.1% TWEEN20. Subsequently 0.5 x PBS + 
casein (0.5 mg ml
-1
) + GST antibodies (1.5 µl ml
-1
) (Amersham Biosciences) was added to the 
filters and incubation was made for one hour in room temperature where after filters were 
washed with PBS + 0.1% TWEEN20. Thereafter 0.5 x PBS + casein (0.5 mg ml
-1
) + 
secondary antibodies from goat labeled with peroxidase (1.5 µl ml
-1
) (Sigma Aldrich, 
Steinheim Germany) was added and filters were incubated for one hour in room temperature 
and washed with PBS + 0.1% TWEEN20 and subsequently with PBS. Development of filters 
was made with PBS + 25 % 4-chloronaphtol + H2O2 (0.8 µl ml
-1
). 
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Results and Discussion 
 
Construction of Clones 
Truncated constructs of the FNE protein were successfully amplified by PCR, as shown in 
Figure 4. The expected lengths of the PCR products were 624 nucleotides for c1, 447 
nucleotides for c2, 267 nucleotides for c3, 513 nucleotides for c4, 576 nucleotides for c5, 765 
nucleotides for c6, 645 for n1, 561 for n2, 375 for n3, 783 nucleotides for n0, 117 nucleotides 
for n4 and 96 nucleotides for n5. The subsequent gel electrophoresis revealed that the 
obtained lengths of the constructs were in agreement with the calculated lengths.  
 
 
 
                 
Figure 4. Agarose gel picture of PCR-amplified constructs; (1) DNA Marker 0.5 µg/µl Kilobase (0.5-
10 kbp), (2) eq52c1, (3) eq52c2, (4) eq52c3, (5) eq52n1, (6) eq52n2 and (7) eq52n3, (8) DNA Marker 
0.5 µg/µl Kilobase, (9) eq52c4, (10) eq52c5, (11) eq52c6, (12) eq52n0, (13) eq52n4 and (14) eq52n5.  
 
 
Results from the sequencing showed that a single base pair substitution had taken place in 
clone eq52c6, hence resulting in an amino acid substitution; amino acid K245 was replaced 
with amino acid R245. However, as the two amino acids K and R are relatively similar we 
decided to go on with the constructs despite the mutation. One explanation for the base pair 
change could be that the non proof reading enzyme, Taq DNA polymerase, introduced the 
change, or that the sequencing process did not work out properly. Sending the DNA samples 
for sequencing in duplicates could have confirmed or refused this theory.  
 
Protein Expression and Purification 
The protein constructs from FNE were expressed using the Glutathione Sepharose (GST) 
expression system (Appendix III) that uses IPTG, a synthetic lactose analog, as transcription 
activator. IPTG induces expression of cloned genes under control of the lac operon. 
Transcription of the lac operon, which in this case is replaced with the gene of interest, is 
induced when IPTG binds to the lac repressor. Inactivation of the lac repressor induces 
synthesis of the enzyme beta-galactosidase that promotes lactose utilization by binding and 
inhibiting the lac repressor. 
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   Purification of the expressed proteins was analyzed using SDS-PAGE (Fig. 5 and 6). The 
gel picture (Fig. 5) shows that construct eq52c3 was susceptibly small and a second analysis 
of the sequence revealed mutations in one primer, just before the protein sequence, resulting 
in a base pair exchange and expression only of the GST protein. The sequence for the second 
clone of the construct eq52c3 was therefore analyzed where after this clone was used for the 
subsequent analyses.  
 
 
 
Figure 5. SDS-PAGE with purified proteins from constructs; (1) Broad Range Protein Ladder (xxx), 
(2) eq52c1, (3) eq52c2, (4) eq52c3 (GST), (5) eq52n1, (6) eq52n2 and (7) eq52n3.  
 
 
Constructs eq52c3-5 were hardly visible in the first gel run, but since the spectrophotometric 
measurements (Table 3) indicated presence of proteins samples were concentrated, 
approximately three times, and thereafter run on a second gel. This gel showed presence of 
construct eq52c5 but not of constructs eq25c3 and eq52c4. However, as subsequent 
spectrophotometric measurements showed presence of all constructs a third gel, with non-
diluted samples and three times as much material added to the wells, was run. Western 
blotting of the gels (Fig. 6) showed presence of all constructs, although constructs eq52c3, 
eq52c4 and eq52n0 gave a lot weaker bands than remaining constructs. Even though the 
concentrations of constructs eq52c3 and eq52c4 seemed to be lower than calculated, this did 
not affect the results as the limits for collagen- binding were given from constructs eq52c2 
and eq52c5. Moreover, this assay showed several bands for most of the constructs (Fig. 6). 
Bands above the expected size are most probably dimers or trimers of the proteins and bands 
underneath the expected sizes are likely to represent proteins degraded by proteases in the 
host cell. The high spectrophotometric values were most probably due to presence of 
background and could possibly have been prevented by a longer dialysis course. 
   In general, constructs truncated from the N-terminal gave higher protein yields than 
constructs truncated from the C-terminal, indicating that the C-terminal includes amino acids 
important for the existence and stability of the protein. Figure 7 gives a schematic 
presentation of the FNE protein and the truncated constructs eq52c1-c6 and eq52n0-n5.  
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Figure 6. Western blot picture from SDS-PAGE gel run; (1) eq52c1, (2) eq52c2, (3) eq52c3, (4) 
eq52c4, (5) eq52c5, (6) eq52c6, (7) eq52n0, (8) eq52n1, (9) eq52n2, (10) eq52n3, (11) eq52n4 and 
(12) eq52n5.  
 
Table 3. OD280 values, calculated protein concentrations and total protein yield for the different 
constructs; eq52c1, eq52c2, eq52c3, eq52c4, eq52c5, eq52c6, eq52n0, eq52n1, eq52n2, eq52n3, 
eq52n4 and eq52n5 (ExPASy-ProtParam, 2007). 
Construct Protein concentration 
(µg/ml) 
Total yield  
(mg) 
eq52c1 400 0.80 
eq52c2 120 0.24 
eq52c3 240 0.24 
eq52c4 180 0.18 
eq52c5 440 0.22 
eq52c6 170 0.34 
eq52n0 740 1.48 
eq52n1 620 1.24 
eq52n2 450 0.90 
eq52n3 950 1.90 
eq52n4 250 0.50 
eq52n5 210 0.42 
 
 
 
 
 
Figure 7. Schematic presentation of the FNE protein and truncated proteins eq52n0-n5 and eq52c1-c6.  
 
Protein Interaction Assays 
The capacity of the different constructs to bind fibronectin and/or collagen was assayed by dot 
blotting, repeated twice for each construct. Table 4 shows that fibronectin binding is 
constricted to the C-terminal part of the protein whereas collagen binding regions seem to be 
present in both N- and C-termini. In general, binding to fibronectin gave stronger signals than 
binding to collagen. This is in agreement with a previous study made by Lidén et al. (2008). 
   The fibronectin binding region could be further mapped since construct eq52n4 does bind 
fibronectin and construct eq52n5 does not. Hence the amino acid sequence GLEGGSS (amino 
acids G228 - S234) can be considered required for fibronectin-binding in the FNE protein. 
This theory is further supported by the fact that construct eq52c1 does not bind fibronectin 
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and construct eq52c6 does. In addition, the N-terminal located fibronectin binding domain in 
FNZ has been shown to be located between amino acids S227 and H341, beginning with the 
amino acid sequence SGLEGGXS, which is a repeated motif in the FNZ protein (Lindmark et 
al. 1996a).  
   Collagen binding is still present when 5 amino acids are removed from the N-terminal, but 
disappears when removing 15 amino acids. Moreover, the collagen binding also disappears 
when FNE is truncated from the C-terminal. Binding is still present when 57 amino acids are 
removed from the C-terminal, but disappears when removing 116 amino acids. These results 
indicate that the collagen-binding domain is large and starts at approximately amino acid Y5 
and ends in the region of amino acid G200. The size of this region is in agreement with 
collagen-binding regions found in other proteins as well (Lannergård 2006).  
 
 
Table 4. Binding capacities to fibronectin and collagen for clones eq52c1-6 and eq52n0-5. Binding 
assays were performed by dot blotting. Binding is indicated with + and no binding is indicated with -. 
Construct Fibronectin Collagen 
eq52c1 - + 
eq52c2 - - 
eq52c3 - - 
eq52c4 - - 
eq52c5 - - 
eq52c6 + + 
eq52n0 
eq52n1 
eq52n2 
eq52n3 
eq52n4 
eq52n5 
+ 
+ 
+ 
+ 
+ 
- 
+ 
- 
- 
- 
- 
- 
Antibody Interaction Assay 
A western blot assay, where serum and GST antibodies were added to two filters respectively, 
was performed in order to determine if antibodies against FNE are directed to a specific part 
of the protein. Results from the assay (Table 5) clearly show that the C-terminal part of the 
protein is essential for interaction with antibodies against FNE. Antibody interaction is not 
weakened when truncating 58 amino acids from the C-terminal, but weakens a lot when 
truncating 117 amino acids. Truncating the protein 104 amino acids from the N-terminal end 
does not affect the antibody interaction. However, this assay was made on proteins run on 
SDS-PAGE gels where proteins are denatured, i.e. the secondary and non-disulfide-linked 
tertiary structures are lost, which could affect the recognition of the antibodies.  
 
 
Table 5. Level of interaction between constructs and antibodies against FNE and GST respectively. + 
indicates weak interaction and +++ indicates very strong interaction.  
Construct Filter 1  
(serum) 
Filter 2  
(GST antibodies) 
eq52c1 +++ +++ 
eq52c2 + +++ 
eq52n1 +++ +++ 
eq52n2 +++ +++ 
eq52n3 +++ +++ 
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A second antibody interaction assay was performed in order to evaluate the interaction level 
of remaining clones as well as the significance of the secondary and non-disulfide-linked 
tertiary structures in antibody recognition and binding. Antibodies against the N-terminal part 
of FNZ generated in rabbit gave very strong signals for the intact FNE protein as well as for 
construct eq52c1 (Table 6). Constructs eq52c3, eq52n4 and eq52n5 gave no interaction at all 
and remaining constructs gave fairly strong signals for interaction, taking into account the 
somewhat different concentrations of the proteins used. The lack of signals for constructs 
eq52c3, eq52n4 and eq52n5 indicates that the amino acids between K89 and G227 are 
important for the interaction with antibodies. Results from this study coincide with results 
from the Western blot assay (Table 5), thus confirming the importance of the amino acids 
between K89 and G227 for detection by antibodies. Interestingly, antibodies seem to be 
directed to the part of the protein with most activity considering collagen- and fibronectin 
binding (Table 4).  
   Sera from healthy horses as well as sera from horses recovered from strangles gave very 
low titers (Table 6). However, this result is not surprising since sera contain antibodies against 
a vast number of bacteria and foreign molecules, i.e. a lower concentration of antibodies 
against FNE. Moreover, it has earlier been shown (Lannergård 2006) that, during S. equi 
subsp. equi infection, no general antibody response is generated against Fn- binding proteins. 
Still, the results from this assay show similarities to the results from the preceding antibody 
assays, i.e. antibodies interact with amino acids located between K89 and G227. Increased 
serum concentration in these assays could perhaps have given stronger interaction between 
sera and the different constructs. However, reduced amounts of sera available made further 
studies unfeasible.  
 
 
Table 6. Level of interaction for truncated proteins and wild type protein with antibodies against FNE 
generated in rabbit, sera from healthy horses and sera from horses recovered from strangles 
respectively. +++ indicates very strong interaction whereas + indicates weak interaction. 
Construct Filter 1 
(antibodies against FNE 
generated in Rabbit) 
Filter 2 
(sera from healthy 
horses) 
Filter 3 
(sera from horses 
recovered from strangles) 
FNE +++ - + 
eq52c1 +++ - + 
eq52c2 + - + 
eq52c3 - - - 
eq52c4 + - - 
eq52c5 + - - 
eq52c6 ++ - - 
eq52n0 + - - 
eq52n1 ++ - + 
eq52n2 ++ + + 
eq52n3 ++ - + 
eq52n4 - - - 
eq52n5 - - - 
 
Inhibition Assays 
To determine if antibody interaction with the constructs could inhibit the fibronectin- and/or 
collagen-binding properties an inhibition assay was performed. Results (Table 7) show that 
collagen-binding is completely inhibited for all constructs whereas fibronectin-binding only is 
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partly inhibited. The partial inhibition of fibronectin could be due to differences in amounts of 
protein, as complete inhibition only can be attained if antibodies are in adequate surplus. The 
results from this assay confirm the results from previous assays, where it was stated that 
antibodies against the N-terminal part of FNZ are directed to a site between amino acids K89 
and G227. This site is located partly in the binding region for collagen and near the binding 
region for fibronectin and it is therefore proposed that the size of the antibodies sterically 
hinders the fibronectin binding.  
 
 
Table 7. Interaction with fibronectin and collagen of constructs eq52c6, eq52n0 ad eq52n4 after 
incubation with antibodies against FNE.  
Construct Fibronectin Collagen 
eq52c6 - - 
eq52n0 + - 
eq52n4 + - 
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Conclusions 
 
Experiments performed in this project revealed interesting and important information about 
the FNE protein.   
   Fibronectin- binding was shown to be constricted to the C-terminal part of the protein and 
the amino acid sequence GLEGGSS (amino acids G228 - S234) seem to be required for the 
binding. This was in concordance with results from experiments performed with the FNZ 
protein from S. equi subsp. zooepidemicus (Lindmark et al. 1996), where the repeated amino 
acid sequence SGLEGGXS was shown to bind fibronectin. The collagen binding region was 
shown to be a large domain, starting at approximately amino acid 5 and ending in the region 
of amino acid 200, also in agreement with previous studies. In general, interaction with 
fibronectin gave stronger signals than interaction with collagen, which was in agreement with 
a previous study made by Lidén et al. (2008). 
   Moreover it was shown, by dot blotting and western blotting, that rabbit polyclonal 
antibodies against the N-terminal of the FNZ protein are directed against a region between 
amino acids K89 and G227 in the FNE protein. This region covers part of the collagen-
binding region and ends near the fibronectin-binding region. In addition, the inhibition assays 
revealed that interaction with antibodies inhibit collagen- binding and suppress fibronectin- 
binding of the FNE protein. Thus, suggesting that the antibodies sterically hinder collagen- 
and fibronectin- binding, which is an important and interesting finding considering the 
potential role of FNE in edema formation. It may be possible that antibodies directed against 
FNE could affect edema formation and thus milder the symptoms of the disease. Though, 
further studies are needed in order to establish the results. Antibody assays with sera from 
healthy horses as well as sera from horses recovered from strangles gave very low titers. 
However, results from these assays were in line with the other antibody assays; antibodies are 
directed against the region between amino acid K89 and G227. 
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Appendix I 
Nucleotide and protein sequence of the FNE protein with truncations from the C-terminal end 
marked C1-C6 and truncations from the N-terminal end marked N0-N5. The last amino acid 
in constructs truncated from the C-terminal end is colored purple whereas the first amino acid 
in constructs truncated from the N-terminal end is colored yellow.  
 
 
 
gagcagctttattatggg 
       E  Q  L  Y  Y  G  
              
tggaatgatggaacgagacaaagttcgccatattttttgtacgtatcgcctaaaaatgct 
 W  N  D  G  T  R  Q  S  S  P  Y  F  L  Y  V  S  P  K  N  A  
 
ccaaagcgtgaattaaaagacgagtatgttgtttattgctttaacaaaaaattgtattgg 
 P  K  R  E  L  K  D  E  Y  V  V  Y  C  F  N  K  K  L  Y  W  
 
ccagatcaatgggaatctatatacagcaattttaatgacatcagatctccatataacgat 
 P  D  Q  W  E  S  I  Y  S  N  F  N  D  I  R  S  P  Y  N  D  
 
ttacctgtatatgagaaaaaactaggatatgatggtatatttaaacaatatgctccagat 
 L  P  V  Y  E  K  K  L  G  Y  D  G  I  F  K  Q  Y  A  P  D  
                                             
tacaaaaaagatattagtgatatcgcaagtgctttggtggcagttttaagtaatggatac 
 Y  K  K  D  I  S  D  I  A  S  A  L  V  A  V  L  S  N  G  Y  
 
cccactaacaagtcacaactatcaactagctaccatttaaataatgattcttctagaaaa 
 P  T  N  K  S  Q  L  S  T  S  Y  H  L  N  N  D  S  S  R  K  
 
gttactcaattagccatttggtattttagtgatagtttaacaaaagaataccttaaagat 
 V  T  Q  L  A  I  W  Y  F  S  D  S  L  T  K  E  Y  L  K  D  
 
acgggtggttataacttaaacgatatggaaaaaaaagctttagattttttaatcagtaaa 
 T  G  G  Y  N  L  N  D  M  E  K  K  A  L  D  F  L  I  S  K  
 
ggagaggattctaagcttaaatcagagcagagtaattactcattggatatttatgtttat 
 G  E  D  S  K  L  K  S  E  Q  S  N  Y  S  L  D  I  Y  V  Y  
 
caaagtggcgggcatgaccatatgaaagattaccaaaatcttctcggctctaccttaatt 
 Q  S  G  G  H  D  H  M  K  D  Y  Q  N  L  L  G  S  T  L  I  
 
cctaaagaaccgctaaagcctcagctaggtggttttagtggacataatggaaatggatta 
 P  K  E  P  L  K  P  Q  L  G  G  F  S  G  H  N  G  N  G  L  
 
agcggccttgaaggaggatcatcaggttcacaagaaactaatgaagatggtaagaaagga 
 S  G  L  E  G  G  S  S  G  S  Q  E  T  N  E  D  G  K  K  G  
                                                 
cttataggtttccatggaggactctcaggaagcgagggcaaacgagatcctttccaggat 
 L  I  G  F  H  G  G  L  S  G  S  E  G  K  R  D  P  F  Q  D  
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Appendix II 
 
Map of the pGEX-6P vectors showing reading frames and main features (Amersham 
Biosciences). 
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Appendix III 
Glutathione S-transferase (GST) Gene Fusion System 
 
